著者
Tomohito Hamazaki Harumi Okuyama Akira Tanaka Yasuo Kagawa Yoichi Ogushi Rokuro Hama
出版者
Japan Society for Lipid Nutrition
雑誌
脂質栄養学 (ISSN:13434594)
巻号頁・発行日
vol.21, no.1, pp.67-75, 2012 (Released:2012-04-29)
被引用文献数
1

Almost all Japanese epidemiological studies showed that all-cause mortality was lower in subjects with high serum total or LDL-cholesterol levels. Studies showing the disadvantage of high cholesterol levels included or were likely to include more participants with FH than in the general Japanese population. This also explains why epidemiological studies with elderly people are not able to detect any disadvantage of high cholesterol levels; groups of elderly subjects contain a smaller proportion of vulnerable FH patients who die earlier than those without FH. Meta-analyses of the effects of statins were used to indicate the favorable effects of these drugs, which might be considered as proof that cholesterol has unfavorable effects. However, the absolute effect size of statins on all-cause mortality is rather small, if any. Moreover, studies included in meta-analyses of statins were performed before the new clinical research regulation came into effect in 2005-2006 in the EU, which required clinical trial results to be published even if the data were not favorable for the tested drugs (BJOG 2007; 114: 917, http://www.bjog.org/view/0/index.html). Considering the fact that placebo-controlled clinical trials performed after the new regulation were mostly negative (J Lipid Nutr 2010; 19: 65, http://www.jstage.jst.go.jp/article/jln/19/1/65/_pdf/-char/ja/), the results published before the regulation were questionable and should not be used as the basis for recommendations for treatment with cholesterol-lowering medications. Because the relative risks of high cholesterol for CHD vary from 5, administering cholesterol-lowering medications to all Japanese individuals equally is not rational; at least women and elderly men need to be carefully re-examined because no or little positive associations between plasma cholesterol and CHD mortality rates have been reported in these groups.
著者
Michel de Lorgeri Patricia Salen
出版者
Japan Society for Lipid Nutrition
雑誌
脂質栄養学 (ISSN:13434594)
巻号頁・発行日
vol.19, no.1, pp.65-92, 2010 (Released:2010-05-01)
参考文献数
46
被引用文献数
2 2

The cholesterol-lowering drug trials published in 2008-2009 were either negative (ENHANCE, SEAS, GISSI-HF, AURORA) or obviously biased and therefore not credible (JUPITER). How can we explain this wave of negative cholesterol-lowering drug trials? In this article, authors review and comment the results of these recent trials. It is also noteworthy that most cholesterol-lowering drug trials published between 2005 (the year of the Vioxx affair and of enforcement of new clinical trial regulations) and 2007 were also negative or ambiguous. Taken together, these recent trials, including those of 2008-2009, strongly suggest that the results of previous, highly positive trials with statins - particularly in the secondary prevention of coronary heart disease - published between 1994 and 2004 and that were used to issue guidelines for medical practitioners should be carefully re-examined by experts independent from the pharmaceutical industry. The next question would be whether it is not time for a full reappraisal of the theory according to which cholesterol-lowering results in a significant protection against cardiovascular morbidity and mortality.
著者
川端 輝江
出版者
Japan Society for Lipid Nutrition
雑誌
脂質栄養学 (ISSN:13434594)
巻号頁・発行日
vol.15, no.1, pp.37-45, 2006-03-31 (Released:2009-04-10)
参考文献数
11

The range of intakes, that is, the upper and lower limits of intake, of the fat energy ratio, saturated fatty acids, n-6 series fatty acids, n-3 series fatty acids and cholesterol have been laid down in the Dietary Reference Intakes (DRIs) for Japanese, 2005. However, it is not easy, even for nutrition specialists, such a dietitians who manage daily dietary intakes, to understand the DRIs of lipids, for which there are so many reference values. It would be rather difficult in daily dietary management to control the intake of various lipid-containing foods to satisfy the DRIs of the various components of lipids. Therefore, in this paper, we describe how the DRIs of lipids should be understood from the viewpoint of users, and an example composition of food groups that could be available in the future is shown.